Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peposertib × Gynecologic × 90 days × Clear all
NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡